<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?DTDIdentifier.IdentifierValue article.dtd?>
  <?DTDIdentifier.IdentifierType system?>
  <?SourceDTD.DTDName article.dtd?>
  <?SourceDTD.Version 1.0?>
  <?ConverterInfo.XSLTName bmc2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Negat Results Biomed</journal-id>
      <journal-title-group>
        <journal-title>Journal of Negative Results in Biomedicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-5751</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3104374</article-id>
      <article-id pub-id-type="publisher-id">1477-5751-10-5</article-id>
      <article-id pub-id-type="pmid">21554703</article-id>
      <article-id pub-id-type="doi">10.1186/1477-5751-10-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>N-acetylcysteine lacks universal inhibitory activity against influenza A viruses</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Garigliany</surname>
            <given-names>Mutien-Marie O</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>mmgarigliany@ulg.ac.be</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Desmecht</surname>
            <given-names>Daniel J</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>daniel.desmecht@ulg.ac.be</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Pathology, Faculty of Veterinary Medicine, University of Li&#xE8;ge, Belgium</aff>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>10</volume>
      <fpage>5</fpage>
      <lpage>5</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>11</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>5</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2011 Garigliany and Desmecht; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Garigliany and Desmecht; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.jnrbm.com/content/10/1/5"/>
      <abstract>
        <p>N-acetylcysteine (NAC) has been recently proposed as an adjuvant therapeutic drug for influenza pneumonia in humans. This proposal is based on its ability to restrict influenza virus replication <italic>in vitro </italic>and to attenuate the severity of the disease in mouse models. Although available studies were made with different viruses (human and avian), published information related to the anti-influenza spectrum of NAC is scarce. In this study, we show that NAC is unable to alter the course of a fatal influenza pneumonia caused by inoculation of a murinized swine H1N1 influenza virus. NAC was indeed able to inhibit the swine virus <italic>in vitro </italic>but far less than reported for other strains. Therefore, susceptibility of influenza viruses to NAC appears to be strain-dependent, suggesting that it cannot be considered as a universal treatment for influenza pneumonia.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>About 10 percent of the human population is affected by influenza annually and several pandemic episodes have occurred throughout recorded history [<xref ref-type="bibr" rid="B1">1</xref>]. This context explains why continued efforts are made to identify new therapeutic molecules. Among these, N-acetylcysteine (NAC), which is commonly used for its mucolytic activity in humans, was shown to inhibit influenza virus both in mouse models, alone or in combination, with the A/PR/8 strain [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>], and <italic>in vitro</italic>, with H5N1 strains [<xref ref-type="bibr" rid="B4">4</xref>]. Recently, NAC treatment was reported to reduce symptoms of influenza-like illness in humans [<xref ref-type="bibr" rid="B5">5</xref>] and administration of the dose of 100 mg/kg supposedly contributed to the success of the treatment of a patient infected with the 2009 pandemic H1N1 virus [<xref ref-type="bibr" rid="B6">6</xref>].</p>
      <p>In order to determine whether these successful results can be extrapolated to other viral strains than A/PR/8 and H5N1 strains, the effect of NAC on the clinical course and outcome of experimental influenza was assessed in mice inoculated with a lethal dose of our murinized swine H1N1 influenza strain [<xref ref-type="bibr" rid="B7">7</xref>]. In spite of a significant but very partial anti-influenza effect <italic>in vitro</italic>, neither percent survival nor body weight loss were altered by NAC treatment <italic>in vivo</italic>, suggesting that NAC-susceptibility of influenza A viruses is strain-dependent.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <sec>
        <title><italic>In </italic><italic>vivo </italic>study</title>
        <p>Two groups of ten 8-wk old female CD-1 mice were intranasally inoculated with 10 MLD50 of murinized A/swine/Iowa/4/1976 (H1N1) virus [<xref ref-type="bibr" rid="B7">7</xref>]. The first group received 100 mg/kg NAC (Sigma) daily by gavage, from day 1 to day 7 post-infection (pi), while the second received the vehicle only. Clinical status, body weight (BW) and mortality were recorded daily up to day 14 pi. Challenge studies were approved by the Belgian Council for Laboratory Animal Science, under the guidance of the Institutional Animal Care and Use Committees of the University of Li&#xE8;ge.</p>
      </sec>
      <sec>
        <title><italic>In </italic><italic>vitro </italic>study</title>
        <p>Near confluent Vero cells (ATCC CCL-81) were infected at a multiplicity of infection of 0.01 with a Vero cell-adapted variant of the A/swine/Iowa/4/1976 (H1N1) virus in 6-well plates. One hour after infection, fresh DMEM supplemented with 0.2% bovine serum albumin (Invitrogen), 2 &#x3BC;g/ml TPCK-treated trypsin (Sigma), and either 0, 0.5, 1.5 or 2.5 mg/ml of NAC (Sigma) was added onto the cells. Culture supernatants were harvested 48 h after infection and titrated by standard plaque assays.</p>
      </sec>
    </sec>
    <sec>
      <title>Results and discussion</title>
      <p>All mice became obviously sick from day 5 pi onward, with lethargy, ruffled coat and respiratory distress. Percent survival and mean survival time (Figure <xref ref-type="fig" rid="F1">1</xref>) were not different between NAC and control groups (p &gt; 0.05, Kaplan-Meier analysis). Moreover, course and amplitude of BW loss (Figure <xref ref-type="fig" rid="F2">2</xref>) were similar (p &gt; 0.05, ANOVA). Altogether, the results therefore show that a daily dose of 100 mg/kg NAC did not confer protection against influenza disease in our experimental conditions. The dose of NAC given here (100 mg/kg) is typically that used for high dose NAC treatment of human severe influenza pneumonia in recent clinical trials [<xref ref-type="bibr" rid="B6">6</xref>]. Some of the former studies that have enlighted the protective efficacy of NAC in mouse models have used an oral dose of 1000 mg/kg, which suggests that the dose given here is not sufficient. However, 100 mg/kg NAC is already considered as a high dose in humans, and 1000 mg/kg is obviously unrealistic for humans because too close to the LD50 [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. The fact that a dose of NAC close to that used here drastically diminished mouse lung damages in a diesel-enhanced influenza pneumonia [<xref ref-type="bibr" rid="B10">10</xref>] whereas it did not work here rather suggests that the use of different virus strains results in different susceptibilities to NAC <italic>in vivo</italic>.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Kaplan-Meier survival analysis after H1N1 virus inoculation in mock- and N-acetylcysteine-treated mice (n = 10)</bold>.</p>
        </caption>
        <graphic xlink:href="1477-5751-10-5-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Effect of mock and N-acetylcysteine oral treatment on body weight course after inoculation of 10 DL50 of H1N1 virus in mice</bold>. Means &#xB1; SD (n = 10).</p>
        </caption>
        <graphic xlink:href="1477-5751-10-5-2"/>
      </fig>
      <p>To examine this hypothesis further, the susceptibility to NAC of our porcine H1N1 strain was assessed <italic>in vitro </italic>by mimicking Geiler and colleagues methodological approach [<xref ref-type="bibr" rid="B4">4</xref>]. We also found a dose-dependent inhibition of influenza virus replication by NAC (Figure <xref ref-type="fig" rid="F3">3</xref>). However, even a very high dose (2.5 mg/ml, about 15 mM) resulted in a &#x2248; 6-fold reduction of virus yield, which is far less than that observed with H5N1 [<xref ref-type="bibr" rid="B4">4</xref>]. Thus, the anti-influenza activity of NAC appears to be strain-dependent as already supposable from previous studies [<xref ref-type="bibr" rid="B4">4</xref>]. The porcine A/swine/Iowa/4/1976 (H1N1) strain used here seems more resistant to NAC than the human strains A/PR/8/1934 (H1N1) and A/Hong Kong/8/1968 (H3N2) used by other authors in mouse models [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. The lack of protection <italic>in vivo </italic>recorded in our experimental conditions is therefore probably associated to a combination of the NAC-resistance phenotype and to the pathotype [<xref ref-type="bibr" rid="B7">7</xref>] of the virus strain used.</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Effect of N-Acetylcysteine on swine H1N1 virus replication in Vero cells</bold>. Vero cells were infected with A/swine/Iowa/4/1976 (H1N1) at a MOI of 0.01. N-acetylcysteine treatment was started 1 hour post-infection and continued up to 48 hours post-infection. Viral titers were determined 48 hours post-infection. Data represent the mean &#xB1; SD of two independent experiments.</p>
        </caption>
        <graphic xlink:href="1477-5751-10-5-3"/>
      </fig>
      <p>Overall, the <italic>in vitro </italic>and <italic>in vivo </italic>results gathered here show that susceptibility of influenza viruses to NAC is clearly strain-dependent, which suggests that NAC cannot be considered to be a universal treatment for influenza pneumonia. A systematic testing of anti-influenza activity of NAC should be implemented whenever a new strain emerges.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>NAC: N-acetylcysteine; TPCK: L-1-tosylamido-2-phenylethyl chloromethyl ketone.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>MMG designed the study, performed the experiments and helped to draft the manuscript. DD initiated the study, participated in the analysis and interpretation of data, and drafted the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Simonsen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Fukuda</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Schonberger</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Cox</surname>
            <given-names>NJ</given-names>
          </name>
          <article-title>The impact of influenza epidemics on hospitalizations</article-title>
          <source>J Infect Dis</source>
          <year>2000</year>
          <volume>181</volume>
          <fpage>831</fpage>
          <lpage>837</lpage>
          <pub-id pub-id-type="doi">10.1086/315320</pub-id>
          <pub-id pub-id-type="pmid">10720501</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ungheri</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Pisani</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sanson</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bertani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Schioppacassi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Delgado</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Sironi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ghezzi</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Protective effect of n-acetylcysteine in a model of influenza infection in mice</article-title>
          <source>Int J Immunopathol Pharmacol</source>
          <year>2000</year>
          <volume>13</volume>
          <fpage>123</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="pmid">12657201</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ghezzi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Ungheri</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model</article-title>
          <source>Int J Immunopathol Pharmacol</source>
          <year>2004</year>
          <volume>17</volume>
          <fpage>99</fpage>
          <lpage>102</lpage>
          <pub-id pub-id-type="pmid">15000873</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Geiler</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Michaelis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Naczk</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Leutz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Langer</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Doerr</surname>
            <given-names>HW</given-names>
          </name>
          <name>
            <surname>Cinatl</surname>
            <given-names>J</given-names>
            <suffix>Jr</suffix>
          </name>
          <article-title>N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus</article-title>
          <source>Biochem Pharmacol</source>
          <year>2010</year>
          <volume>79</volume>
          <fpage>413</fpage>
          <lpage>420</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2009.08.025</pub-id>
          <pub-id pub-id-type="pmid">19732754</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>De Flora</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Grassi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Carati</surname>
            <given-names>L</given-names>
          </name>
          <article-title>Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment</article-title>
          <source>Eur Respir J</source>
          <year>1997</year>
          <volume>10</volume>
          <fpage>1535</fpage>
          <lpage>1541</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.97.10071535</pub-id>
          <pub-id pub-id-type="pmid">9230243</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lai</surname>
            <given-names>KY</given-names>
          </name>
          <name>
            <surname>Ng</surname>
            <given-names>WY</given-names>
          </name>
          <name>
            <surname>Osburga Chan</surname>
            <given-names>PK</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>KF</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
          <article-title>High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia</article-title>
          <source>Ann Intern Med</source>
          <year>2010</year>
          <volume>152</volume>
          <fpage>687</fpage>
          <lpage>688</lpage>
          <pub-id pub-id-type="pmid">20479037</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Garigliany</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Habyarimana</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lambrecht</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Van de Paar</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Cornet</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>van den Berg</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Desmecht</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice</article-title>
          <source>Emerg Infect Dis</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>595</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="pmid">20350372</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Garozzo</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tempera</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ungheri</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Timpanaro</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Castro</surname>
            <given-names>A</given-names>
          </name>
          <article-title>N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection</article-title>
          <source>Int J Immunopathol Pharmacol</source>
          <year>2007</year>
          <volume>20</volume>
          <fpage>349</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="pmid">17624247</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="other">
          <article-title>American International Chemical, Acetylcysteine Material Safety Data Sheet</article-title>
          <ext-link ext-link-type="uri" xlink:href="http://www.aicma.com/msds/Acetylcysteine%20USP.pdf">http://www.aicma.com/msds/Acetylcysteine%20USP.pdf</ext-link>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gowdy</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Krantz</surname>
            <given-names>QT</given-names>
          </name>
          <name>
            <surname>King</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Boykin</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Jaspers</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Linak</surname>
            <given-names>WP</given-names>
          </name>
          <name>
            <surname>Gilmour</surname>
            <given-names>MI</given-names>
          </name>
          <article-title>Role of oxidative stress on diesel-enhanced influenza infection in mice</article-title>
          <source>Part Fibre Toxicol</source>
          <year>2010</year>
          <volume>7</volume>
          <fpage>34</fpage>
          <pub-id pub-id-type="doi">10.1186/1743-8977-7-34</pub-id>
          <pub-id pub-id-type="pmid">21092162</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
